Cytodyme

Excited to share what we’ve been building at Cytodyme! Join us for Techstars San Diego powered by San Diego State University Fall 2025 Demo Day on December 4 at Snapdragon Stadium as we showcase our progress alongside some of San Diego’s most promising startups including ORBES, Laibl (Techstars ’25), HapWare (Techstars '25), Klira AI, and Landng. We can’t wait to connect with the community that’s been cheering us on! Register here: https://luma.com/2n91fc62

Cytodyme is halfway through the Fall 2025 Techstars San Diego powered by San Diego State University accelerator and we’re making meaningful progress every week. We’ve been in back-to-back mentor sessions, deep in customer discovery, building our platform, and connecting with the San Diego startup community. We’ve also had a strong presence at events like Innovation Night at the La Jolla Playhouse and Connect Forward, and were featured as a Top 30 Startup at San Diego Startup Week. Out of more than 1,300 applicants, Cytodyme was one of just six startups selected for this cohort, and we’re incredibly proud of the growth we’ve made as we gear up for Demo Day in December. We’re in great company alongside ORBES, Laibl (Techstars ’25), HapWare (Techstars '25), Klira AI, and Landng. Huge thanks to Misti Cain, Jonah Peake 🐺, Hunter Haines, Neal Bloom🎩, Cheryl K Goodman, Lisa Barnhouse, Rick Moy, Randy Tsudama, James Zanewicz, JD, LLM, RTTP, Taryn Goode, Terry Arbaugh, Cathy Pucher, Hala Madanat, Erica Charlonis, Eric Otterson, Alessandro Rinaldi, Erika Gastelum, Manuel Jaime, Alex Altomare, Jon Langbert, Jack Bixby Lucas, Rebecca Deller, Tim Schwartz and the Sullivan Center for Entrepreneurship and Innovation for all the mentorship and support that’s gotten us this far!

Techstars San Diego powered by San Diego State University has been an incredible experience so far. Our team spent the past two weeks in “mentor magic,” meeting with seven mentors a day. We’re only a few weeks in, and it’s already been such a valuable experience. Huge thanks to everyone who shared their time and perspective to help us keep pushing forward!

Cytodyme is excited to announce that we have been selected to join Techstars San Diego! We are glad to be building in our home town, thanks Techstars and SDSU for having us! More exciting news to come!

The FDA Has an AI Tool. What About Everyone Else? We have just published a new piece on why regulatory innovation, like Elsa, is only one part of the equation and what biotech teams need to do now to stay ahead.   Read the full blog here: https://lnkd.in/gmVnUxPn

The FDA’s launch of Elsa, its in-house generative AI tool, is a strong signal that the agency is serious about improving internal efficiency. It’s a great first step, targeting low-risk, high-friction tasks like summarizing adverse events and parsing clinical protocols. But to fully realize the promise of AI in life sciences, we need to push the boundaries further. A faster FDA is only part of the equation. If biotech teams, external partners like CDMOs and CROs, and other stakeholders are still working in silos, bogged down by manual documentation and fragmented systems, we won’t see the full benefit of a more responsive regulator. Real transformation happens when both industry and regulators are equipped with tools that speak the same language, share context seamlessly, and reduce the bottlenecks between innovation and approval. Elsa helps reviewers move faster. We’re focused on helping the rest of the ecosystem keep up. Check out the news release here: https://lnkd.in/eTr--bPF More about Cytodyme: www.cytodyme.com

Veeva’s recent article on compliance in MedTech highlights a mindset gap that’s just as common in biotech. In large companies, regulatory know-how is baked into the culture. There are entire teams dedicated to quality, and decades of experience to draw from. However, in early-stage biotech, especially in founder-led teams without prior regulatory experience, that institutional knowledge is often missing or is costly to hire or contract out. Compliance ends up feeling abstract. Or worse, like a blocker. But when it's built into the process early, it gives teams the edge they need to avoid missteps that can slow everything down. A strong regulatory process isn’t just about staying compliant. It creates structure, reduces rework, and helps teams avoid costly delays. For early-stage biotech companies, that kind of foundation can make the difference between momentum and months of backtracking. At Cytodyme, we help biotech teams bridge that gap by streamlining and automating the documentation and compliance process. The goal is to give teams a faster and clearer path forward, whether they’re navigating clinical development for the first time or scaling established processes. This article is worth a read: https://lnkd.in/esjXxCCs More on Cytodyme: www.cytodyme.com

NFX just published a piece asking why longevity, despite being a trillion-dollar opportunity, is still being overlooked by investors. The science is here. Cellular reprogramming, synthetic biology, and advanced delivery systems are no longer speculative. The infrastructure exists. What’s missing is the visibility investors need to back the companies positioned to turn science into outcomes.   The post compares longevity to the early days of AI, when the core technology was in place but the surrounding ecosystem hadn’t caught up. The opportunity was real, but most people didn’t yet know how to evaluate it or where to place their bets.   That’s exactly where Cytodyme is focused: helping breakthrough therapies move from the lab into real development.   Our tool supports the infrastructure behind these companies by removing one of the biggest sources of friction in clinical development: documentation. We guide teams through the creation of compliant, submission-ready records with built-in regulatory checks, so they can reduce errors, avoid delays, and stay on track toward clinical and commercial milestones.   By supporting execution at the operational level, Cytodyme helps biotech teams reduce regulatory risk and become stronger candidates for funding. If longevity is going to grow, it needs tools that help great science translate into investable companies.   Read the post: https://lnkd.in/eGRaMRwC More on Cytodyme: www.cytodyme.com

🔔 THE FIRST DEMO PREVIEW IS HERE! 💢 Creating clinical documentation is painfully time consuming. Hundreds of documents, thousands of hours to develop. ✅ Let us automate it for you! 😃 In this preview demo we share how Cytodyme's AI powered platform can detect missing documents in your workflows and generate them instantly. 📆 Schedule a full demo: cytodyme.com/demo More previews to come! Follow along! Building in the open, feedback welcome! #BiotechInnovation #LifeSciences #RegulatoryCompliance #AIInBiotech #aiworkflows #aiagents #FDA

🔔 DEMO ALERT! 💢 Creating clinical documentation is painfully time consuming. Hundreds of documents, thousands of hours to develop. ✅ Let us automate it for you! 😃 In our upcoming sneak peek demo we are sharing how Cytodyme's AI powered platform can detect missing documents in your workflows and generate them instantly. 📆 Schedule a full demo: cytodyme.com/demo #BiotechInnovation #LifeSciences #RegulatoryCompliance #AIInBiotech #aiworkflows #aiagents #FDA